Solu Therapeutics Debuts with $31 Million in Seed Funding to Unlock Antibody-Intractable Cell Surface Targets
Solu Therapeutics
We warmly welcome the interest of reporters in our firm and the companies we support: we’re also happy simply to help journalists working on stories in deep tech.
To reach us, email press@dcvc.com.